Semprus BioSciences to Present at SIR's 36th Annual Scientific Meeting

Christopher Loose, Ph.D., to Present New Data on Semprus Platform

CAMBRIDGE, MA - (March 14, 2011) - Semprus BioSciences today announced its Chief Technology Officer Christopher Loose, Ph.D., will present the company's groundbreaking data results on its non-fouling Semprus Platform at the Society of Interventional Radiology's (SIR) 36th Annual Scientific Meeting in Chicago, Ill., on Monday, March 28, 2011.

Dr. Loose will present Semprus' data on its single-surface modification that demonstrate simultaneous reduction of microbial and platelet adhesion over multiple months. These data showcase the technology's three distinctive aspects: its dual-functionality, its ability to work in blood products, and its long-term durational advantages over existing surface and coating technologies.

SIR's Annual Meeting is a recognized forum for peer-reviewed presentations of new research by interventional radiologists and allied scientists from around the world. It provides a host of news and educational opportunities ranging from scientific presentations and news conferences to hands-on workshops and technical exhibits.

Semprus BioSciences is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. The company's current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device. The company spun out of the labs of biomedical researcher and Massachusetts Institute of Technology (MIT) Professor Robert Langer, Sc.D., in 2007.

"It's a great privilege for us to present our novel technology at SIR's annual meeting," said Chief Executive Officer David L. Lucchino. "We are very proud of our technology and excited to highlight the aspects that distinguish it from other surface and coating technologies currently on the market."

Dr. Loose will present at the Venous Access/Thrombolysis Scientific Session on Monday, March 28, at 8:30 a.m. in Room W181C, McCormick Place West Building.

About Semprus BioSciences

Semprus BioSciences is a venture-backed biomedical company headquartered in Cambridge, Massachusetts. The company's innovative, multi-faceted Semprus technology signifies a breakthrough in medical device technology. Its current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device. In December 2010, the company completed an $18 million Series B financing co-led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners (FMP), a national healthcare venture capital investment firm with a strategic relationship with Cleveland Clinic. Combined with previous financing rounds, Semprus has raised a total of $28.5 million in equity.

Visit http://www.semprusbio.com for additional information.

Semprus BioSciences won Frost & Sullivan's "2010 North American Enabling Technology of the Year Award for Surface in Functionalization Technologies" for its Semprus Platform in December 2010.


Semprus BioSciences was selected as one of "50 Companies to Watch" by Medical Devices & Diagnostics Industry magazine in June 2010.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.